Braveheart Bio, Inc.

NASDAQ: BRVE · Healthcare · Biotechnology

PublicHQ San Francisco, CA · San FranciscoCIK 0002131524Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 44

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-09-07

Market cap

$1.9B

as of 2026-09-07

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Braveheart Bio, Inc.’s financial profile?

Braveheart Bio, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Alamar Biosciences, Inc.——Kailera Therapeutics, Inc.——Generate Biomedicines, Inc.——Damora Therapeutics, Inc.——Tyra Biosciences, Inc.——Bicara Therapeutics Inc. Common Stock——

Neighbors

San Francisco →

Visa Inc.$40.0B86A Wells Fargo & Company$85.1B55C Salesforce, Inc.$41.5B80B+Uber Technologies, Inc.$52.0B71B Prologis, Inc.$8.8B67B Airbnb, Inc.$12.2B66B

Key facts

CEOTravis Murdoch

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Francisco, CA

ExchangeNASDAQ: BRVE

Employees30

IPO date2026-08-06

Latest filings

10-Q2026-09-08 8-K2026-09-08 8-K2026-08-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.